Pfizer’s COVID-19 Vaccine 90 Percent Effective: Initial Data

Vaccine experts say the results surpass their expectations, but the study is not complete, and the data have not been peer reviewed.

Written byMax Kozlov
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

ABOVE: © ISTOCK.COM,
TERO VESALAINEN

Update (November 18): After the companies concluded their Phase 3 trials and found that the vaccine is 95 percent effective in an analysis of 170 confirmed COVID-19 cases, Pfizer and BioNTech are expected to seek emergency authorization from global regulators within days. The results put the vaccine on par with competitor Moderna’s COVID-19 vaccine, which was found on Monday to be 94.5 percent effective in a preliminary analysis of 95 participants.

Preliminary data from pharmaceutical giant Pfizer and German biotechnology firm BioNTech show that their COVID-19 vaccine is more than 90 percent effective at protecting people from the infection, compared to patients who received a placebo saline shot, according to a Pfizer statement today (November 9).

“I’ve been in vaccine development for 35 years,” William Gruber, Pfizer’s senior vice president of vaccine clinical research and development, tells STAT. “I’ve seen some really good things. This is ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Max is a science journalist from Boston. Though he studied cognitive neuroscience, he now prefers to write about brains rather than research them. Prior to writing for The Scientist as an editorial intern in late 2020 and early 2021, Max worked at the Museum of Science in Boston, where his favorite part of the job was dressing in a giant bee costume and teaching children about honeybees. He was also a AAAS Mass Media Fellow, where he worked as a science reporter for the St. Louis Post-Dispatch. Read more of his work at www.maxkozlov.com.

    View Full Profile
Share
Image of small blue creatures called Nergals. Some have hearts above their heads, which signify friendship. There is one Nergal who is sneezing and losing health, which is denoted by minus one signs floating around it.
June 2025, Issue 1

Nergal Networks: Where Friendship Meets Infection

A citizen science game explores how social choices and networks can influence how an illness moves through a population.

View this Issue
An illustration of green lentiviral particles.

Maximizing Lentivirus Recovery

cytiva logo
Unraveling Complex Biology with Advanced Multiomics Technology

Unraveling Complex Biology with Five-Dimensional Multiomics

Element Bioscience Logo
Resurrecting Plant Defense Mechanisms to Avoid Crop Pathogens

Resurrecting Plant Defense Mechanisms to Avoid Crop Pathogens

Twist Bio 
The Scientist Placeholder Image

Seeing and Sorting with Confidence

BD

Products

The Scientist Placeholder Image

Waters Enhances Alliance iS HPLC System Software, Setting a New Standard for End-to-End Traceability and Data Integrity 

The Scientist Placeholder Image

Agilent Unveils the Next Generation in LC-Mass Detection: The InfinityLab Pro iQ Series

agilent-logo

Agilent Announces the Enhanced 8850 Gas Chromatograph

parse-biosciences-logo

Pioneering Cancer Plasticity Atlas will help Predict Response to Cancer Therapies